CRSP vs NTLA

CRISPR Therapeutics remains a high-potential player in gene editing, positioned for transformative growth. The successful commercialization of Casgevy (with Vertex) and planned pediatric filings in H1 2026 solidify its market entry and de-risk early revenue generation, albeit with a reported ~97.8% YoY revenue decline in an unspecified recent period, indicating challenges in early commercial ramp-...

Intellia Therapeutics continues to demonstrate strong execution in its pioneering gene-editing pipeline. The positive Phase 3 data for lonvo-z in HAE and the initiation of its rolling BLA submission, targeting a 1H 2027 launch, are transformative. The FDA's lifting of clinical holds on nex-z trials further de-risks its broader platform. While the company remains unprofitable, its Q1 2026 earnings ...